StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Shares of NASDAQ GNCA opened at $0.00 on Thursday. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00. The company has a market cap of $5,873.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Featured Articles
- Five stocks we like better than Genocea Biosciences
- 3 Warren Buffett Stocks to Buy Now
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.